Research
Thesis
Investigation of Biomarker determinants of treatment efficacy of fulvestrant and the AKT inhibitor AZD5363 in Oestrogen receptor positive breast cancer
Publications
2024
- Vasileva-Slaveva, M., Morales-Espinosa, D., Puccini, A., Meissner, M., Milic, M., Lamberti, G. and Altena, R. 2024. Tackling hurdles in front of young clinical investigators in oncology – Results from an international survey. European Journal of Surgical Oncology 50(6), article number: 108031. (10.1016/j.ejso.2024.108031)
2023
- Meissner, M., Napolitano, A., Thway, K., Huang, P. and Jones, R. L. 2023. Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?. Expert Opinion on Pharmacotherapy 24(12), pp. 1395-1401. (10.1080/14656566.2023.2224500)
2022
- Howell, S. J. et al. 2022. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology 23(7), pp. 851-864. (10.1016/s1470-2045(22)00284-4)
2021
- Meissner, M. 2021. Investigation of biomarker determinants of treatment response of fulvestrant and capivasertib in oestrogen receptor positive breast cancer. PhD Thesis, Cardiff University.
2016
- Meissner, M. and Addeo, A. 2016. Intrathecal methotrexate and craniospinal radiotherapy can be an effective treatment of carcinomatous meningitis in patients with breast cancer: case reports. Case Reports in Oncology 9(3), pp. 586-592. (10.1159/000449448)